Corrigendum to "Quantitative analysis of clonal bone marrow CD19+ B cells: Use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis" [Clin. Immunol. 120 (2006) 106-120] (DOI:10.1016/j.clim.2006.01.008);Quantitative analysis of clonal bone marrow CD19+ B cells: Use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis

Clinical Immunology

Volumn 120, Issue 1, 2006, Pages 106-120

  Manske, Michelle K ^a   Zuckerman, Neta S ^b   Timm, Michael M ^a   Maiden, Stephanie ^c   Edelman, Hanna ^b   Shahaf, Gitit ^b   Barak, Michal ^b   Dispenzieri, Angela ^a   Gertz, Morie A ^a   Mehr, Ramit ^b   Abraham, Roshini S ^a  

^a Mayo Clinic   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

B cells; Clone; Human; Immunoglobulin light chain amyloidosis; Monoclonal gammopathy; Plasma cell dyscrasia

Indexed keywords

CD19 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; SYNDECAN 1;

ALGORITHM; AMYLOIDOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL CLONE; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LIGHT CHAIN AMYLOIDOSIS; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MUTATION; NUCLEOTIDE SEQUENCE; PLASMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; STEM CELL; UNINDEXED SEQUENCE;

EID: 33745173514     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.09.017     Document Type: Erratum

References (41)

1. Kyle R.A., and Greipp P.R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin. Proc. 58 10 (1983) 665-683
2. Kyle R.A., and Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 32 1 (1995) 45-59
3. Gertz M.A., and Kyle R.A. Primary systemic amyloidosis-A diagnostic primer. Mayo Clin. Proc. 64 12 (1989) 1505-1519
4. Gertz M.A., Lacy M.Q., and Dispenzieri A. Amyloidosis. Hematol. Oncol. Clin. North Am. 13 6 (1999) 1211-1233
5. Perfetti V., Ubbiali P., Magni M., Colli Vignarelli M., Casarini S., Matteucci P., Gianni A.M., and Merlini G. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplant. 23 4 (1999) 323-327
6. Comenzo R.L., Michelle D., LeBlanc M., Wally J., Zhang Y., Kica G., Karandish S., Arkin C.F., Wright D.G., Skinner M., and McMannis J. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. [see comment]. Transfusion 38 1 (1998) 60-69
7. Billadeau D., Ahmann G., Greipp P., and Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 178 3 (1993) 1023-1031
8. Billadeau D., Van Ness B., Kimlinger T., Kyle R.A., Therneau T.M., Greipp P.R., and Witzig T.E. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88 1 (1996) 289-296
9. Billadeau D., Quam L., Thomas W., Kay N., Greipp P., Kyle R., Oken M.M., and Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80 7 (1992) 1818-1824
10. Witzig T.E., Dhodapkar M.V., Kyle R.A., and Greipp P.R. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72 1 (1993) 108-113
11. Gertz M.A., Witzig T.E., Pineda A.A., Greipp P.R., Kyle R.A., and Litzow M.R. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 19 4 (1997) 337-342
12. Mitterer M., Oduncu F., Lanthaler A.J., Drexler E., Amaddii G., Fabris P., Emmerich B., Coser P., and Straka C. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. [see comment]. Br. J. Haematol. 106 3 (1999) 737-743
13. Caligaris-Cappio F., Bergui L., Tesio L., Pizzolo G., Malavasi F., Chilosi M., Campana D., van Camp B., and Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J. Clin. Invest. 76 3 (1985) 1243-1251
14. Bergsagel P.L., Masellis-Smith A., Belch A.R., and Pilarski L.M. The blood B cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr. Top. Microbiol. Immunol. 199 (1994) 17-24
15. Bergsagel P.L., Smith A.M., Szczepek A., Mant M.J., Belch A.R., and Pilarski L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. [erratum appears in Blood 1995 Jun 1;85(11):3365]. Blood 85 2 (1995) 436-447
16. Perfetti V., Bellotti V., Garini P., Zorzoli I., Rovati B., Marinone M.G., Ippoliti G., and Merlini G. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab. Invest. 71 6 (1994) 853-861
17. Pilarski L.M., Masellis-Smith A., Szczepek A., Mant M.J., and Belch A.R. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk. Lymphoma 22 5-6 (1996) 375-383
18. Perfetti V., Vignarelli M.C., Bellotti V., Glennie M.J., Zorzoli I., Ubbiali P., Obici L., Massa M., Ippoliti G., Ascari E., and Merlini G. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells. Lab. Invest. 77 4 (1997) 333-344
19. O'Connor B.P., Cascalho M., and Noelle R.J. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195 6 (2002) 737-745
20. Kocks C., and Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc. Natl. Acad. Sci. U. S. A. 85 21 (1988) 8206-8210
21. Manser T. Evolution of antibody structure during the immune response. The differentiative potential of a single B lymphocyte. J. Exp. Med. 170 4 (1989) 1211-1230
22. Jacob J., Kelsoe G., Rajewsky K., and Weiss U. Intraclonal generation of antibody mutants in germinal centres. [see comment]. Nature 354 6352 (1991) 389-392
23. Dunn-Walters D.K., Boursier L., and Spencer J. Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells. Eur. J. Immunol. 27 11 (1997) 2959-2964
24. Vora K.A., Tumas-Brundage K., and Manser T. Contrasting the in situ behavior of a memory B cell clone during primary and secondary immune responses. J. Immunol. 163 8 (1999) 4315-4327
25. Shannon M., and Mehr R. Reconciling repertoire shift with affinity maturation: the role of deleterious mutations. J. Immunol. 162 7 (1999) 3950-3956
26. Mehr R., Edelman H., Sehgal D., and Mage R. Analysis of mutational lineage trees from sites of primary and secondary Ig gene diversification in rabbits and chickens. J. Immunol. 172 8 (2004) 4790-4796
27. Dunn-Walters D.K., Belelovsky A., Edelman H., Banerjee M., and Mehr R. The dynamics of germinal centre selection as measured by graph-theoretical analysis of mutational lineage trees. Dev. Immunol. 9 4 (2002) 233-243
28. Dunn-Walters D., Edelman H., and Mehr R. Immune system learning and memory quantified by graphical analysis of B-lymphocyte phylogenetic trees. BioSystems 76 (2004) 141-155
29. Abraham R.S., Geyer S.M., Price-Troska T.L., Allmer C., Kyle R.A., Gertz M.A., and Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101 10 (2003) 3801-3808
30. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., Ser. B, Methodol. 57 1 (1995) 289-300
31. Lossos I.S., Tibshirani R., Narasimhan B., and Levy R. The inference of antigen selection on Ig genes. J. Immunol. 165 9 (2000) 5122-5126
32. Johnson K.M., Owen K., and Witte P.L. Aging and developmental transitions in the B cell lineage. Int. Immunol. 14 11 (2002) 1313-1323
33. Shahaf G., Johnson K.M., and Mehr R. B cell development in aging mice: Lessons from mathematical modeling. Int. Immunol. 18 1 (2005) 31-39
34. Shlomchik M.J., Marshak-Rothstein A., Wolfowicz C.B., Rothstein T.L., and Weigert M.G. The role of clonal selection and somatic mutation in autoimmunity. Nature 328 6133 (1987) 805-811
35. Kepler T.B. Codon bias and plasticity in immunoglobulins. Mol. Biol. Evol. 14 6 (1997) 637-643
36. Dunn-Walters D.K., and Spencer J. Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. Immunology 95 3 (1998) 339-345
37. Hamburger A., and Salmon S.E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 60 4 (1977) 846-854
38. Barker H.F., Ball J., Drew M., and Franklin I.M. Multiple myeloma: the biology of malignant plasma cells. Blood Rev. 7 1 (1993) 19-23
39. Yaccoby S., and Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94 10 (1999) 3576-3582
40. Pilarski L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., and Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95 3 (2000) 1056-1065
41. Matsui W., Huff C.A., Wang Q., Malehorn M.T., Barber J., Tanhehco Y., Smith B.D., Civin C.I., and Jones R.J. Characterization of clonogenic multiple myeloma cells. Blood 103 6 (2004) 2332-2336